April 21, 2020
Schwendinger M et al. J Infect Dis 2020;jiaa121.
A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus
You might also be interested by
CellTalk
Regulation-Compliant Flow Cytometry Analysis With CellEngine®
October 12, 2022
Immune Monitoring
More infoCellTalk
CellEngine®: Transitioning to the Next Generation of Cytometry Analysis Software
September 12, 2022
Immune Monitoring
More infoCellTalk
Confidently Measure Target Engagement With Receptor Occupancy Assays by Flow Cytometry
August 9, 2022
Immune Monitoring
More infoBrochures
High Performance Technologies for Cytokine Measurement
November 8, 2021
Immune Monitoring
More info